IL6 and age-related macular degeneration: Unlike Vascular Endothelial Growth Factor (VEGF) -inhibitors used intravitreally for treating exudative age-related macular degeneration, which have a short half-life in the eye of just a few days [35], no similar data exists for the anti-IL-6 antibody.